Quarterly report pursuant to Section 13 or 15(d)

Intangibles, net

v3.19.2
Intangibles, net
6 Months Ended
Jun. 30, 2019
Intangibles, net  
Intangibles, net

9. Intangibles, net

The table below provides a summary of the JMC intangible asset as of June 30, 2019 and December 31, 2018, respectively:

 

 

 

 

 

 

 

 

 

 

 

Estmated Useful

 

June 30, 

 

December 31, 

($ in thousands)

    

Lives (Years)

    

2019

    

2018

 

 

 

 

(Unaudited)

 

 

 

Ceracade®

 

 3

 

$

300

 

$

300

Luxamend®

 

 3

 

 

50

 

 

50

Targadox®

 

 3

 

 

1,250

 

 

1,250

Exelderm®

 

 3

 

 

1,200

 

 

1,200

Total

 

  

 

 

2,800

 

 

2,800

Accumulated amortization

 

  

 

 

(1,829)

 

 

(1,383)

Net intangible assets

 

  

 

$

971

 

$

1,417

 

The table below provides a summary for the six months ended June 30, 2019, of JMC recognized expense related to its product licenses, which was recorded in costs of goods sold on the Condensed Consolidated Statement of Operations:

 

 

 

 

 

 

Intangible

($ in thousands)

    

Assets

Beginning balance at January 1, 2019

 

$

1,417

Amortization expense

 

 

(446)

Ending balance at June 30, 2019

 

$

971

 

The future amortization of these intangible assets is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

($ in thousands)

    

Targadox®

    

Exelderm®

    

Amortization

For the six-months ending December 31, 2019

 

$

104

 

$

200

 

$

304

December 31, 2020

 

 

 —

 

 

400

 

 

400

December 31, 2021

 

 

 —

 

 

267

 

 

267

Total

 

$

104

 

$

867

 

$

971